Imagion Biosystems 2020 Full Year Results

2020 Highlights: MagSense™ HER2 breast cancer Phase I study initiated Collaboration with Siemens Healthineers explores MagSense™ nanoparticles using MRI Total…


Quarterly Activity Report for 31 December 2020 — Appendix 4C

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 December 2020 (Q4…


Imagion Biosystems December 2020 Investor Newsletter

Imagion Biosystems is pleased to provide its investors with its December 2020 Investor Newsletter. The newsletter details recent new company developments and…


First In-human Study Update: Study Open for Enrolment

Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for…


IBX Raises $6M in Placement

Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP. Placement strongly supported by…


New Imaging Technology for Early Detection

Early detection is critical to improving cancer survival rates. Too often, the limitations of today's medical imaging technologies result in cancer being…


Appendix C and Quarterly Activity Report

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 30 September 2020 (Q3…


Quarterly Activity Report and Appendix C

Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…


Imagion Biosystems Appoints Geoff Hollis as CFO

Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the…


HREC Approval for Phase I Study

Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense™ HER2 Phase I study…